Global eCOA Leadership Kayentis is a global leader in electronic Clinical Outcome Assessments (eCOA) and decentralized trials, with operations across the US, Europe, and Asia. The platform supports Phase I-IV trials across hundreds of indications and therapeutic areas, underscoring broad applicability. This creates strong cross-sell opportunities with pharma, biotech, and CROs for end-to-end data capture, patient-centric workflows, and integration services.

Strategic Partnerships Recent and prior partnerships with RWS, ClinOne, and Omnicomm demonstrate a proven ecosystem for co-selling technology and services. This offers a clear path for business development to propose integrated solutions that combine eCOA with training, analytics, or adaptive trial capabilities. Target collaborations with AI, data science, and patient engagement platforms to win larger, multi-therapeutic studies.

Growth Funding Kayentis has secured growth financing in 2020 and 2023, signaling investor confidence and the ability to scale operations. With mid-market scale and reported revenue in the 10–25 million USD range, Kayentis can support expanding trial programs and larger customer commitments. Use this to position Kayentis as a scalable partner for more complex, multicenter trials.

Market Breadth Broad clinical coverage across 200 indications and 20 therapeutic areas indicates strong market reach and a patient-centric focus. This enables tailored propositions for diverse patient populations, regulatory environments, and global trial footprints. Consider pilots and flexible per-site pricing to win multi-indication or global trials with CROs and pharma customers.

Interoperability and Integration Kayentis leverages a modern tech stack designed for integration with existing eClinical ecosystems, backed by clinical leadership such as a Medical Director to validate adoption. Position Kayentis as a compatible partner for multi-system data ecosystems, offering API and integration options to complement downstream analytics and AI initiatives.